In the ATTRACTION-1 trial, PD-1 inhibitor nivolumab combined with chemotherapy for unresectable esophageal cancer had a trend toward longer survival with the 5-year OS was 6.3% and 5-year PFS was 6.8% (Ikeda et al., 2024). The gene discussed is PDCD1; the disease is esophageal cancer.